All In Biotech

Drug Trial Radar · NCT02327078

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

307

Actual

Start

Nov 26, 2014

Primary completion

Jun 16, 2020

Study completion Jun 16, 2020

Sponsor

Lead sponsor
Incyte CorporationIncyte (INCY)
Sponsor type
Industry
Collaborators
Bristol-Myers Squibb
First posted
Dec 30, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, open label study. Phase 1 consists of 2 parts. Part 1 is a dose-escalation assessment of the safety and tolerability of epacadostat administered with nivolumab in subjects with select advanced solid tumors and lymphomas. Part 2 will evaluate the safety and tolerability of epacadostat in combination with nivolumab and chemotherapy in subjects with squamous cell carcinoma of head and neck (SCCHN) and non-small cell lung cancer (NSCLC). Phase 2 will include expansion cohorts in 7 tumor types, including melanoma, NSCLC, SCCHN, colorectal cancer, ovarian cancer, glioblastoma and diffuse large B-cell lymphoma (DLBCL).

Conditions

  • B-cell Malignancies
  • Colorectal Cancer (CRC)
  • Head and Neck Cancer
  • Lung Cancer
  • Lymphoma
  • Melanoma
  • Ovarian Cancer
  • Glioblastoma

Interventions

  • NivolumabDrug

    specified dose and dosing schedule

  • EpacadostatDrug

    oral twice daily continuous at the protocol-defined dose

  • ChemotherapyDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1, Part 1: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Day 42
  2. Phase 1, Part 2: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Day 42
  3. Phase 1, Parts 1 and 2: Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE)Time frame: up to approximately 39 months
  4. Phase 2: Objective Response Rate (ORR) in Participants With Select Solid Tumors Per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1 for Participants With Solid Tumors and Per Cheson Criteria for Participants With DLBCLTime frame: From first dose up end of the study (up to approximately 6 years)
  5. Phase 2: Progression Free Survival (PFS)Time frame: From first dose up end of the study (up to approximately 6 years)
  6. Phase 2: Overall Survival (OS) Rate of Proportion With GlioblastomaTime frame: Month 9

Locations

24 sites in 2 countries. Site status is shown where the registry gives one.

  • UAB Comprehensive Cancer Center

    Birmingham, Alabama

  • The Angeles Clinic and Research Institute

    Los Angeles, California

  • USC Norris Cancer Center

    Los Angeles, California

  • UCSF - University of California San Francisco

    San Francisco, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • The University of Kansas Clinical Research Center

    Fairway, Kansas

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts

  • NYU Cancer Center

    New York, New York

  • Columbia University, Herbert Irving Comprehensive Cancer Center

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Wake Forest Medical Center Boulevard

    Winston-Salem, North Carolina

  • Sanford Research

    Fargo, North Dakota

  • University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania

  • Sanford Research

    North Sioux City, South Dakota

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Oncology Research

    Austin, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • Huntsman Cancer Institute

    Salt Lake City, Utah

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Oxford University Hospitals NHS Trust

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.